More specifically, patients in the control group with high levels of PTX3 and PAA patients with low levels of PTX3 would have been less likely included in the analytical sample, which is unlikely and difficult to fully address given the available data. The gene discussed is PTX3; the disease is pulmonary artery-aorta diameter ratio measurement.